Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

BCX7353

Plasma kallikrein inhibitor

DRUG

Placebo

Trial Locations (24)

Adelaide

Campbelltown

Graz

Vienna

Québec

Toronto

Odense

Berlin

Frankfurt

Ulm

Budapest

Milan

Padua

Salerno

Skopje

Barcelona

Madrid

Seville

Zurich

Brimingham

Bristol

London

Oxford

Southampton